[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Synergetics Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":73},{"warningLetters":4,"total":72},[5,30,52],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":24,"medical_device_id":19,"response_letter_date":19},2834,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-03-01T20:00:00Z\">03\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-03-01T05:00:00Z\">03\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynergy-mixing-labs-llc-625235-03012022\">Synergy Mixing Labs, LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert Jason White\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Synergy Mixing Labs, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4230 West Dunlap Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85051\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Orders4sml@gmail.com\"> Orders4sml@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 1, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. White:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Synergy Mixing Labs, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Cloud Slingers Coco Queen 6mg 120ml, Cloud Slingers Bad Cop 24mg 30ml, and Cloud Slingers Black Pearl 18mg 30ml.\u003C\u002Fp>\n\n\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 2,500 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0001144, on September 10, 2020. However, FDA issued a negative action for STN PM0001144 in the form of a Marketing Denial Order determination on September 10, 2021, which covers 5,334 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0001144 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2200434, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>cc: michelle.stell@gmail.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRobert Jason White\n\nRecipient Title\n\nOwner\n\nSynergy Mixing Labs, LLC\n\n4230 West Dunlap Avenue\n\nPhoenix, AZ 85051\n\nUnited States\n\nOrders4sml@gmail.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 1, 2022\n\nWARNING LETTER\n\nDear Mr. White:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Synergy Mixing Labs, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States the following e-liquid products without a marketing authorization order: Cloud Slingers Coco Queen 6mg 120ml, Cloud Slingers Bad Cop 24mg 30ml, and Cloud Slingers Black Pearl 18mg 30ml.\n\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 2,500 products listed with FDA. FDA received your Premarket Tobacco Product Application (PMTA), assigned STN PM0001144, on September 10, 2020. However, FDA issued a negative action for STN PM0001144 in the form of a Marketing Denial Order determination on September 10, 2021, which covers 5,334 products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your ENDS products covered by STN PM0001144 that resulted in a Marketing Denial Order determination, are adulterated and misbranded. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For more information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2200434, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\ncc: michelle.stell@gmail.com","Synergy Mixing Labs, LLC","synergy-mixing-labs-llc-625235-03012022","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynergy-mixing-labs-llc-625235-03012022","2026-10-26T08:10:09.146641+00:00","Warning Letter","Issued","2022-03-01","625235","Tobacco","Robert Jason White","2026-08-20T02:08:27.794+00:00","VIA UPS and Electronic Mail",{"id":31,"raw":32,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":47,"closeout_date":19,"issuing_office":36,"recipient_name":48,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":51,"medical_device_id":19,"response_letter_date":19},684,[33,34,35,36,37,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-16T04:00:00Z\">07\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynergy-animal-products-inc-712860-07162025\">Synergy Animal Products, Inc. \u003C\u002Fa>","Center for Veterinary Medicine","Unapproved New Animal Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark A. Hassler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Synergy Animal Products, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1681 Schubert Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bethel\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>19507\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:synergyanimalproducts@gmail.com\"> synergyanimalproducts@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 16, 2025\u003C\u002Fp>\u003Cp>Re: 712860\u003C\u002Fp>\u003Cp>Dear Mark A. Hassler,\u003C\u002Fp>\u003Cp>This letter concerns your firm’s marketing of adulterated and misbranded animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&amp;C Act).\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your facility located at 1681 Schubert Rd, Bethel, PA 19507 from September 5, 2024, through September 10, 2024. After a review of the inspection report, and a subsequent review of your website, synergyanimalproducts.com, we have determined that you are marketing drugs for use in animals. Specifically, your website and product labeling establish that your, Ex-Cell Countdown 7000, Natural Cow Herbal Support, Ex-Cell Somaticare, Superior Cow Cream, and Super Cow Udder Mint products are drugs under section 201(g)(1) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. For the reasons discussed below, these products are unapproved new animal drugs. Introducing or delivering these unapproved new animal drugs for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes violations related to the FD&amp;C Act’s labeling requirements for drugs. You distribute drugs that are misbranded under section 502(f)(1) of the FD&amp;C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use.\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes violations of the FD&amp;C Act’s drug manufacturer registration and listing requirements. You do not comply with sections 510(b) and (j) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)] related to drug manufacturer registration and drug listing, and therefore the drugs you distribute are misbranded under section 502(o) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>This Warning Letter also summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), Parts 210 and 211. Because your methods, facilities or controls for manufacturing, processing, packing or holding drugs do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, [21 U.S.C. § 351(a)(2)(B)].\u003C\u002Fp>\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>We reviewed your September 28, 2024, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Animal Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Examples of claims FDA observed on your website, synergyanimalproducts.com, and your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>• \u003Cstrong>Ex-Cell Countdown 7000\u003C\u002Fstrong>\u003Cbr>o “Ex-cell Countdown 7000 is a broad coverage product that is great when you’re unsure of the problem you are having, as well as stringiness and hard quarters.”\u003Cbr>o From your ‘Most Common Recommendations’ infographic:\u003Cbr> “White or Yellow Chunks”\u003Cbr> “High SCC or No Visible Signs”\u003Cbr> “Stringy or Hard Quarter”\u003Cbr> “Thick Consistency”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Natural Cow Herbal Support\u003C\u002Fstrong>\u003Cbr>o “Use for…high somatic cell count, scours…”\u003Cbr>o “Scours in Calves”\u003Cbr>o “High Somatic Cell”\u003Cbr>o “… because of their anti-septic, anti-inflammatory &amp; antibacterial properties.”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Ex-Cell Somaticare\u003C\u002Fstrong>\u003Cbr>o “Use when problems look clear and watery and\u002For may contain flakes.”\u003Cbr>o “This formula is designed to target problems that look clear and watery and\u002For may contain flakes”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Superior Cow Cream\u003C\u002Fstrong>\u003Cbr>o “… Sore Teats – Flaky Milk – High S.C.C”\u003Cbr>o “…works beneath the skins surface at a deeper level than traditional udder creams.”\u003C\u002Fp>\u003Cp>• \u003Cstrong>Super Cow Udder Mint\u003C\u002Fstrong>\u003Cbr>o “Super Cow Udder Mint is not for every mastitis case. In most cases, Superior Cow Cream will work, but if a case is really bad, you want the stronger Super Cow Udder Mint.”\u003Cbr>o “… Sore Teats – Flaky Milk – High Somatic Cell Count”\u003C\u002Fp>\u003Cp>Because your products are intended to diagnose, cure, mitigate, treat, or prevent disease and\u002For intended to affect the structure or any function of the body of animals, they are drugs within the meaning of section 201(g)(1) of the FD&amp;C Act, [21 U.S.C. § 321 (g)(1)]. These products are new animal drugs under section 201(v) of the FD&amp;C Act, [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. The new animal drugs you market are not approved or index listed by FDA, and therefore they are unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act, [21 U.S.C. § 351(a)(5)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Without Adequate Directions for Use\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You distribute drugs that are misbranded under section 502(f)(1) of the FD&amp;C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use. Adequate directions for use include, among other things, statements of all intended uses (indications), routes of administration, and frequency of administration in language understandable by laypersons. 21 CFR 201.5.\u003C\u002Fp>\u003Cp>Your website states: “Q: What are your products used for? A: Our products are a natural support system for dairy animals udder health. Our products are not FDA approved; therefore we cannot make any claims regarding our products’ purpose. It is at the farmers discretion to determine the products use.”\u003C\u002Fp>\u003Cp>Your attempt to avoid making claims about your products’ uses put animals (and the humans who might consume the byproducts of the dairy cows treated with your products) at risk by not giving users adequate directions for safe use of your drugs. You market your products for use by the general public (laypersons)–who do not know the details of your products’ formulations and how to safely use them–unless you provide that information in the product’s labeling. Although your products are unapproved, they are drugs and must therefore bear adequate directions for use, including statements of their intended uses that are understandable by laypersons.\u003C\u002Fp>\u003Cp>For example, with respect to your products’ labeling, (including its labels and the labeling on your website):\u003C\u002Fp>\u003Cp>- \u003Cstrong>Ex-Cell Countdown 7000\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “great when you’re unsure of the problem you are having”,” “stringiness,” and other statements that laypersons may not understand, such as “high S.C.C.”). This product is also missing clear directions on the route of administration.\u003C\u002Fp>\u003Cp>- “\u003Cstrong>Natural Cow Herbal Support\u003C\u002Fstrong>” does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons such as, “High Somatic Cell,” and vague language such as “Irregular milk”).\u003C\u002Fp>\u003Cp>- \u003Cstrong>Ex-Cell Somaticare\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “when problems look clear and watery”) and has no directions indicating how to prepare the product for administration.\u003C\u002Fp>\u003Cp>- \u003Cstrong>Superior Cow Cream\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (“e.g., vague statements such as “Flaky Milk” and terminology not appropriate for laypersons, such as “High S.C.C”) and its labeling contains contradictory directions for frequency of use (1 to 2 fl. oz. after milking for 2 to 5 days as needed, per the label vs. twice a day for 6-10 days, per the labeling on the product’s website at synergyanimalproducts.com).\u003C\u002Fp>\u003Cp>- \u003Cstrong>Super Cow Udder Mint\u003C\u002Fstrong> does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons, such as “High Somatic Cell Count,” and vague language such as “Flaky Milk”).\u003C\u002Fp>\u003Cp>During our review, we noted many other products you sell appear to have similar issues. You should review them all to ensure they contain adequate directions for use.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Drug Registration and Listing Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Sections 510(b) and (j) of the FD&amp;C Act [21 U.S.C. § 360(b), (j)] require that manufacturers of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drugs they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>None of the animal drugs you manufacture are listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the evidence gathered during our inspection, we have determined your firm’s operations are out of compliance with the FD&amp;C Act’s Current Good Manufacturing Practice (CGMP) requirements (section 501(a)(2)(B) of the FD&amp;C Act, [21 U.S.C. § 351(a)(2)(B)]), and the requirements of its implementing regulation for drug products, 21 CFR Parts 210 and 211. Our inspection found that your operations were fundamentally noncompliant with CGMP in that you had no quality unit, had no written procedures applicable to the production and distribution of animal drug products, performed no testing, and kept no records pertaining to the manufacturing of these products.\u003C\u002Fp>\u003Cp>Your failure to manufacture drugs in accordance with CGMP means there is no assurance they meet the safety requirements of the FD&amp;C Act or have the identity and strength, and meet the quality and purity characteristics, which they are represented to possess. Moreover, as you manufacture drugs for use in food-producing animals (dairy cows), your inadequate controls increase the risk that your drugs will inadvertently enter the food supply.\u003C\u002Fp>\u003Cp>During the most recent FDA inspection of your facility, our investigators observed specific CGMP violations, including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1) Failure to establish a quality control unit. (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm has no quality unit (QU) or any procedures for the responsibilities of a QU (including\u002Fbut not limited to setting specifications, performing investigations, reviewing complaints, reviewing production records, conducting annual product reviews, and approving or rejecting procedures, components, labeling, and drug products). During the inspection, you stated you did not consider your products to be animal drugs and therefore you did not establish any CGMP procedures. For the reasons discussed earlier in this letter, your products are animal drugs and are therefore subject to the CGMP requirement. A functioning quality unit with approval and rejection authority is a core element of CGMP.\u003C\u002Fp>\u003Cp>\u003Cstrong>2) Failure to test your drug products for conformance to final specifications. (21 CFR 211.165(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>No release testing was conducted on any animal drug products you manufactured and distributed. Testing each batch of drug products for conformance to specifications, including the identity and strength of each active ingredient, is important to ensure your drugs have the quantity of active ingredient you believe is needed to perform as you intend.\u003C\u002Fp>\u003Cp>\u003Cstrong>3) Failure to test your incoming components for identity, purity, strength, and other appropriate quality attributes. (21 CFR 211.84(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not perform specific identity testing for each shipment of each lot of each component you receive and then test each component for conformity with all appropriate written specifications or otherwise establish the reliability of the supplier’s analyses.\u003C\u002Fp>\u003Cp>The quality of the components you use has a direct effect on the quality of the drug products you manufacture, and testing incoming components for identity is an important step in preventing mislabeled components from being used in manufacturing.\u003C\u002Fp>\u003Cp>Additionally, you do not have written procedures pertaining to incoming components or any associated records including, but not limited to: written procedures related to the receiving of containers, closures, and components; the rejection of nonconforming materials; or supplier qualifications\u002Fsupplier quality agreements. You do not maintain copies of your supplier’s test results (i.e. Certificates of Analysis) for each raw material you use. You use raw materials from multiple outside suppliers.\u003C\u002Fp>\u003Cp>\u003Cstrong>4) Failure to establish written procedures for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. (21 CFR 211.67).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, we observed visibly dirty equipment (e.g., your \u003Cstrong>(b)(4)\u003C\u002Fstrong> tank) that you use to manufacture your drug products.\u003C\u002Fp>\u003Cp>You do not have any written procedures or records for the cleaning and maintenance of equipment that you use to make animal drugs. This includes, but is not limited to: written procedures for cleaning, equipment cleaning validation studies, clean\u002Fdirty hold time studies, and cleaning logs. You also do not have preventative maintenance procedures and maintenance logs.\u003C\u002Fp>\u003Cp>Properly cleaned and maintained equipment is needed to prevent microbiological contamination or cross-contamination between batches of different drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>5) Failure to establish master production and control records for each drug product. (21 CFR 211.186(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have master production and control records for any of the drugs you produce. These documents are the foundation of manufacturing in compliance with CGMP because they describe and define each drug, its formulation, the containers, closures, and labeling to be used, the manufacturing process to be followed (the equipment and process), and the sampling and testing to be performed, among other things. As of the inspection, you did not have formulas for any of your products in writing or any master records of any type. These master records are a basic CGMP requirement and necessary to ensure consistency between batches of drug product.\u003C\u002Fp>\u003Cp>\u003Cstrong>6) Failure to prepare batch production and control records for each batch of drug product produced. (21 CFR 211.188).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not keep any written records (i.e., batch records) to document your manufacturing process.\u003C\u002Fp>\u003Cp>Batch records are critical for a variety of reasons, such as facilitating review of the production process before batch release, performing investigations, and performing recalls. You have no records to establish what lots of what components were used, how much of each component was actually added, or what manufacturing processes were performed, and you would be unable to evaluate the need for a recall if, for example, there was a recall on a lot of one of the components you used.\u003C\u002Fp>\u003Cp>In summary, you violate the FD&amp;C Act’s CGMP requirement by:\u003Cbr>- using untested components from suppliers you did not qualify; (\u003Cstrong>violation 3 above\u003C\u002Fstrong>)\u003Cbr>- to manufacture drugs with no defined process or written formulation (i.e., no master production record); (\u003Cstrong>violation 5 above\u003C\u002Fstrong>)\u003Cbr>- using equipment which we observed to be unclean during our inspection and for which you do not have cleaning procedures; (\u003Cstrong>violation 4 above\u003C\u002Fstrong>)\u003Cbr>- without keeping any written records of what components or equipment you used (i.e., no batch records); (\u003Cstrong>violation 6 above\u003C\u002Fstrong>)\u003Cbr>- without performing any tests to verify the quality of the finished product (e.g., identity and strength of active ingredient); (\u003Cstrong>violation 2 above\u003C\u002Fstrong>)\u003Cbr>- and then released the drugs without the oversight of a quality unit, which should have rejected those drugs for the reasons above. (\u003Cstrong>violation 1 above\u003C\u002Fstrong>)\u003C\u002Fp>\u003Cp>We have considered your response to the Form FDA 483. You acknowledged our concern about the absence of an adequately established quality unit and committed to the establishment of a dedicated QU by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response failed to provide adequate detail and timelines regarding implementation. We are concerned that your complete lack of a quality unit has contributed–and continues to contribute–to a total failure of oversight regarding your CGMP operations. FDA has not received any recent updates from your firm regarding your proposed corrective actions. Additionally, your responses do not consider the need to mitigate any potential risks that may be associated with your CGMP-deficient processes in relation to your distributed products. During the inspection, you acknowledged the conditions cited above generally apply to all drugs you have manufactured since 2017.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and effectiveness of corrective actions and preventive actions. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Conclusion\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review indicates that you are offering for sale unapproved new animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 712860” in the subject line of your email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Cindy L. Burnsteel, DVM\u003Cbr>Acting Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc: info@synergyanimalproducts.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\n\nRecipient:\n\nRecipient Name\n\nMark A. Hassler\n\nRecipient Title\n\nPresident and CEO\n\nSynergy Animal Products, Inc.\n\n1681 Schubert Rd\n\nBethel, PA 19507\n\nUnited States\n\nsynergyanimalproducts@gmail.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nJuly 16, 2025\nRe: 712860\nDear Mark A. Hassler,\nThis letter concerns your firm’s marketing of adulterated and misbranded animal drugs in violation of the Federal Food Drug and Cosmetic Act (FD&C Act).\nThe U.S. Food and Drug Administration (FDA) inspected your facility located at 1681 Schubert Rd, Bethel, PA 19507 from September 5, 2024, through September 10, 2024. After a review of the inspection report, and a subsequent review of your website, synergyanimalproducts.com, we have determined that you are marketing drugs for use in animals. Specifically, your website and product labeling establish that your, Ex-Cell Countdown 7000, Natural Cow Herbal Support, Ex-Cell Somaticare, Superior Cow Cream, and Super Cow Udder Mint products are drugs under section 201(g)(1) of the FD&C Act [21 U.S.C. § 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. For the reasons discussed below, these products are unapproved new animal drugs. Introducing or delivering these unapproved new animal drugs for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nThis Warning Letter also summarizes violations related to the FD&C Act’s labeling requirements for drugs. You distribute drugs that are misbranded under section 502(f)(1) of the FD&C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use.\nThis Warning Letter also summarizes violations of the FD&C Act’s drug manufacturer registration and listing requirements. You do not comply with sections 510(b) and (j) of the FD&C Act [21 U.S.C. § 360(b), (j)] related to drug manufacturer registration and drug listing, and therefore the drugs you distribute are misbranded under section 502(o) of the FD&C Act.\nThis Warning Letter also summarizes significant violations of FDA’s Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), Parts 210 and 211. Because your methods, facilities or controls for manufacturing, processing, packing or holding drugs do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, [21 U.S.C. § 351(a)(2)(B)].\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at www.fda.gov.\nWe reviewed your September 28, 2024, response to our Form FDA 483 in detail.\nUnapproved New Animal Drug Violations\nExamples of claims FDA observed on your website, synergyanimalproducts.com, and your product labeling that show the intended use of your products as drugs include, but are not limited to, the following:\n• Ex-Cell Countdown 7000\no “Ex-cell Countdown 7000 is a broad coverage product that is great when you’re unsure of the problem you are having, as well as stringiness and hard quarters.”\no From your ‘Most Common Recommendations’ infographic:\n “White or Yellow Chunks”\n “High SCC or No Visible Signs”\n “Stringy or Hard Quarter”\n “Thick Consistency”\n• Natural Cow Herbal Support\no “Use for…high somatic cell count, scours…”\no “Scours in Calves”\no “High Somatic Cell”\no “… because of their anti-septic, anti-inflammatory & antibacterial properties.”\n• Ex-Cell Somaticare\no “Use when problems look clear and watery and\u002For may contain flakes.”\no “This formula is designed to target problems that look clear and watery and\u002For may contain flakes”\n• Superior Cow Cream\no “… Sore Teats – Flaky Milk – High S.C.C”\no “…works beneath the skins surface at a deeper level than traditional udder creams.”\n• Super Cow Udder Mint\no “Super Cow Udder Mint is not for every mastitis case. In most cases, Superior Cow Cream will work, but if a case is really bad, you want the stronger Super Cow Udder Mint.”\no “… Sore Teats – Flaky Milk – High Somatic Cell Count”\nBecause your products are intended to diagnose, cure, mitigate, treat, or prevent disease and\u002For intended to affect the structure or any function of the body of animals, they are drugs within the meaning of section 201(g)(1) of the FD&C Act, [21 U.S.C. § 321 (g)(1)]. These products are new animal drugs under section 201(v) of the FD&C Act, [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, new animal drugs must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. §§ 360b, 360ccc, and 360ccc-1]. The new animal drugs you market are not approved or index listed by FDA, and therefore they are unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act, [21 U.S.C. § 351(a)(5)].\nThe introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the FD&C Act, [21 U.S.C. § 331(a)].\nDrugs Without Adequate Directions for Use\nYou distribute drugs that are misbranded under section 502(f)(1) of the FD&C Act, [21 U.S.C. § 352(f)(1)] because their labeling lacks adequate directions for use. Adequate directions for use include, among other things, statements of all intended uses (indications), routes of administration, and frequency of administration in language understandable by laypersons. 21 CFR 201.5.\nYour website states: “Q: What are your products used for? A: Our products are a natural support system for dairy animals udder health. Our products are not FDA approved; therefore we cannot make any claims regarding our products’ purpose. It is at the farmers discretion to determine the products use.”\nYour attempt to avoid making claims about your products’ uses put animals (and the humans who might consume the byproducts of the dairy cows treated with your products) at risk by not giving users adequate directions for safe use of your drugs. You market your products for use by the general public (laypersons)–who do not know the details of your products’ formulations and how to safely use them–unless you provide that information in the product’s labeling. Although your products are unapproved, they are drugs and must therefore bear adequate directions for use, including statements of their intended uses that are understandable by laypersons.\nFor example, with respect to your products’ labeling, (including its labels and the labeling on your website):\n- Ex-Cell Countdown 7000 does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “great when you’re unsure of the problem you are having”,” “stringiness,” and other statements that laypersons may not understand, such as “high S.C.C.”). This product is also missing clear directions on the route of administration.\n- “Natural Cow Herbal Support” does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons such as, “High Somatic Cell,” and vague language such as “Irregular milk”).\n- Ex-Cell Somaticare does not have a clear indication statement that is understandable by laypersons (e.g., vague language such as “when problems look clear and watery”) and has no directions indicating how to prepare the product for administration.\n- Superior Cow Cream does not have a clear indication statement that is understandable by laypersons (“e.g., vague statements such as “Flaky Milk” and terminology not appropriate for laypersons, such as “High S.C.C”) and its labeling contains contradictory directions for frequency of use (1 to 2 fl. oz. after milking for 2 to 5 days as needed, per the label vs. twice a day for 6-10 days, per the labeling on the product’s website at synergyanimalproducts.com).\n- Super Cow Udder Mint does not have a clear indication statement that is understandable by laypersons (e.g., use of terminology not familiar to laypersons, such as “High Somatic Cell Count,” and vague language such as “Flaky Milk”).\nDuring our review, we noted many other products you sell appear to have similar issues. You should review them all to ensure they contain adequate directions for use.\nDrug Registration and Listing Violations\nSections 510(b) and (j) of the FD&C Act [21 U.S.C. § 360(b), (j)] require that manufacturers of drugs, including animal drugs, register their manufacturing establishments with FDA and provide the agency with a list of all the drugs they manufacture. Drugs that are manufactured in unregistered establishments or that have not been listed with FDA are misbranded under section 502(o) of the FD&C Act.\nNone of the animal drugs you manufacture are listed with FDA, nor have they been manufactured in a facility that is registered with FDA. Accordingly, these animal drugs are misbranded. Introduction or delivery for introduction of a misbranded animal drug into interstate commerce is prohibited under section 301(a) of the FD&C Act.\nCurrent Good Manufacturing Practice Violations\nBased on the evidence gathered during our inspection, we have determined your firm’s operations are out of compliance with the FD&C Act’s Current Good Manufacturing Practice (CGMP) requirements (section 501(a)(2)(B) of the FD&C Act, [21 U.S.C. § 351(a)(2)(B)]), and the requirements of its implementing regulation for drug products, 21 CFR Parts 210 and 211. Our inspection found that your operations were fundamentally noncompliant with CGMP in that you had no quality unit, had no written procedures applicable to the production and distribution of animal drug products, performed no testing, and kept no records pertaining to the manufacturing of these products.\nYour failure to manufacture drugs in accordance with CGMP means there is no assurance they meet the safety requirements of the FD&C Act or have the identity and strength, and meet the quality and purity characteristics, which they are represented to possess. Moreover, as you manufacture drugs for use in food-producing animals (dairy cows), your inadequate controls increase the risk that your drugs will inadvertently enter the food supply.\nDuring the most recent FDA inspection of your facility, our investigators observed specific CGMP violations, including, but not limited to, the following:\n1) Failure to establish a quality control unit. (21 CFR 211.22).\nYour firm has no quality unit (QU) or any procedures for the responsibilities of a QU (including\u002Fbut not limited to setting specifications, performing investigations, reviewing complaints, reviewing production records, conducting annual product reviews, and approving or rejecting procedures, components, labeling, and drug products). During the inspection, you stated you did not consider your products to be animal drugs and therefore you did not establish any CGMP procedures. For the reasons discussed earlier in this letter, your products are animal drugs and are therefore subject to the CGMP requirement. A functioning quality unit with approval and rejection authority is a core element of CGMP.\n2) Failure to test your drug products for conformance to final specifications. (21 CFR 211.165(a)).\nNo release testing was conducted on any animal drug products you manufactured and distributed. Testing each batch of drug products for conformance to specifications, including the identity and strength of each active ingredient, is important to ensure your drugs have the quantity of active ingredient you believe is needed to perform as you intend.\n3) Failure to test your incoming components for identity, purity, strength, and other appropriate quality attributes. (21 CFR 211.84(d)).\nYou do not perform specific identity testing for each shipment of each lot of each component you receive and then test each component for conformity with all appropriate written specifications or otherwise establish the reliability of the supplier’s analyses.\nThe quality of the components you use has a direct effect on the quality of the drug products you manufacture, and testing incoming components for identity is an important step in preventing mislabeled components from being used in manufacturing.\nAdditionally, you do not have written procedures pertaining to incoming components or any associated records including, but not limited to: written procedures related to the receiving of containers, closures, and components; the rejection of nonconforming materials; or supplier qualifications\u002Fsupplier quality agreements. You do not maintain copies of your supplier’s test results (i.e. Certificates of Analysis) for each raw material you use. You use raw materials from multiple outside suppliers.\n4) Failure to establish written procedures for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product. (21 CFR 211.67).\nDuring the inspection, we observed visibly dirty equipment (e.g., your (b)(4) tank) that you use to manufacture your drug products.\nYou do not have any written procedures or records for the cleaning and maintenance of equipment that you use to make animal drugs. This includes, but is not limited to: written procedures for cleaning, equipment cleaning validation studies, clean\u002Fdirty hold time studies, and cleaning logs. You also do not have preventative maintenance procedures and maintenance logs.\nProperly cleaned and maintained equipment is needed to prevent microbiological contamination or cross-contamination between batches of different drugs.\n5) Failure to establish master production and control records for each drug product. (21 CFR 211.186(a)).\nYou do not have master production and control records for any of the drugs you produce. These documents are the foundation of manufacturing in compliance with CGMP because they describe and define each drug, its formulation, the containers, closures, and labeling to be used, the manufacturing process to be followed (the equipment and process), and the sampling and testing to be performed, among other things. As of the inspection, you did not have formulas for any of your products in writing or any master records of any type. These master records are a basic CGMP requirement and necessary to ensure consistency between batches of drug product.\n6) Failure to prepare batch production and control records for each batch of drug product produced. (21 CFR 211.188).\nYou do not keep any written records (i.e., batch records) to document your manufacturing process.\nBatch records are critical for a variety of reasons, such as facilitating review of the production process before batch release, performing investigations, and performing recalls. You have no records to establish what lots of what components were used, how much of each component was actually added, or what manufacturing processes were performed, and you would be unable to evaluate the need for a recall if, for example, there was a recall on a lot of one of the components you used.\nIn summary, you violate the FD&C Act’s CGMP requirement by:\n- using untested components from suppliers you did not qualify; (violation 3 above)\n- to manufacture drugs with no defined process or written formulation (i.e., no master production record); (violation 5 above)\n- using equipment which we observed to be unclean during our inspection and for which you do not have cleaning procedures; (violation 4 above)\n- without keeping any written records of what components or equipment you used (i.e., no batch records); (violation 6 above)\n- without performing any tests to verify the quality of the finished product (e.g., identity and strength of active ingredient); (violation 2 above)\n- and then released the drugs without the oversight of a quality unit, which should have rejected those drugs for the reasons above. (violation 1 above)\nWe have considered your response to the Form FDA 483. You acknowledged our concern about the absence of an adequately established quality unit and committed to the establishment of a dedicated QU by (b)(4). However, your response failed to provide adequate detail and timelines regarding implementation. We are concerned that your complete lack of a quality unit has contributed–and continues to contribute–to a total failure of oversight regarding your CGMP operations. FDA has not received any recent updates from your firm regarding your proposed corrective actions. Additionally, your responses do not consider the need to mitigate any potential risks that may be associated with your CGMP-deficient processes in relation to your distributed products. During the inspection, you acknowledged the conditions cited above generally apply to all drugs you have manufactured since 2017.\nCGMP Consultant Recommended\nBased on the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and effectiveness of corrective actions and preventive actions. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. Our review indicates that you are offering for sale unapproved new animal drugs in addition to those listed above. If FDA takes legal action, the action may address all of your unapproved drugs, not just those listed above. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nPlease direct your response to the U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “Reference 712860” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nCindy L. Burnsteel, DVM\nActing Director\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc: info@synergyanimalproducts.com","Synergy Animal Products, Inc.","synergy-animal-products-inc-712860-07162025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsynergy-animal-products-inc-712860-07162025","2026-10-26T08:10:09.096269+00:00","2025-09-02","712860","Animal & Veterinary","Mark A. Hassler","2026-08-19T16:27:37.151+00:00","Via Email","2025-07-16",{"id":53,"raw":54,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":36,"recipient_name":69,"body_fetched_at":70,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":71,"medical_device_id":19,"response_letter_date":19},1106,[55,56,57,36,58,13,13,13],"\u003Ctime datetime=\"2025-01-07T14:20:00Z\">01\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-12T05:00:00Z\">11\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenergetic-essences-llc-dba-pet-essences-696395-11122024\">Energetic Essences, LLC dba Pet Essences\u003C\u002Fa>","New Animal Drug\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Polly Fox\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Energetic Essences, LLC dba Pet Essences\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>(b)(6)\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:help@petessences.com\"> help@petessences.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 12, 2024\u003C\u002Fp>\u003Cp>Re: CMS Case # 696395\u003C\u002Fp>\u003Cp>Dear Polly Fox:\u003C\u002Fp>\u003Cp>This letter concerns your firm’s marketing of an unapproved new animal drug for the treatment of seizures in animals, in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). The United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fpetessences.com\u002F in October to November 2024 and has determined that you offer this product for sale there.\u003C\u002Fp>\u003Cp>Based on our review of your website at the internet address https:\u002F\u002Fpetessences.com\u002Fproducts\u002Fseizures, your product is a drug under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, prevention of disease, and\u002For intended to affect the structure or any function of the body of an animal. This product is an unapproved new animal drug and introducing or delivering this product for introduction into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>You can find the FD&amp;C Act and FDA regulations through links on FDA’s homepage at\u003Cbr>www.fda.gov.\u003C\u002Fp>\u003Cp>The intended use of your \"Seizures\" product is indicated by its name and is also shown by the claims you make for it. Examples of claims FDA observed on your website and product labeling that show the intended use of your product include, but are not limited to the following:\u003C\u002Fp>\u003Cp>From your home website titled “\u003Cstrong>Seizures\u003C\u002Fstrong>” at the URL \u003Ca href=\"https:\u002F\u002Fpetessences.com\u002Fproducts\u002Fseizures:\">https:\u002F\u002Fpetessences.com\u002Fproducts\u002Fseizures:\u003C\u002Fa>\u003C\u002Fp>\u003Cp>• “Our Seizures formula is designed to help reduce the frequency, severity, and duration of seizures in animals.”\u003Cbr>• “We recommend administering it to your pet 2 to 4 times a day to help prevent seizures from occurring.”\u003Cbr>• “…this formula can also be used to manage seizures as they occur.”\u003Cbr>• “…certain physical symptoms like shaking, drooling, and lack of control can be addressed with our formula.”\u003C\u002Fp>\u003Cp>On your home webpage titled “\u003Cstrong>Formulas\u003C\u002Fstrong>” at the URL \u003Ca href=\"https:\u002F\u002Fpetessences.com\u002Fpages\u002Fformulas?_pos=2&amp;_sid=9eb800182&amp;_ss=r:\">https:\u002F\u002Fpetessences.com\u002Fpages\u002Fformulas?_pos=2&amp;_sid=9eb800182&amp;_ss=r:\u003C\u002Fa>\u003C\u002Fp>\u003Cp>• “At the time of a seizure, use Emergency to help the animal recover. Then use Seizure Prevention to help ease the emotional stress associated with seizures. Use it daily…”\u003Cbr>• “Our Seizures formula is designed to help reduce the frequency, severity, and duration of seizures in animals. We recommend administering it to your pet 2 to 4 times a day to help prevent seizures from occurring. However, this formula can also be used to manage seizures as they occur… certain physical symptoms like shaking, drooling, and lack of control can be addressed with our formula….”\u003C\u002Fp>\u003Cp>This product is a new animal drug under section 201(v) of the FD&amp;C Act, [21 U.S.C. 321(v)], because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. This product is not approved or index listed by FDA, and therefore, the product is unsafe within the meaning of section 512(a) of the FD&amp;C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “CMS Case #696395” in the subject line of you\u003Ca>r email.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Neal Bataller, ME, DVM\u003Cbr>Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>Cc: help@petessences.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nPolly Fox\n\nRecipient Title\n\nPresident\n\nEnergetic Essences, LLC dba Pet Essences\n\n(b)(6)\n\nUnited States\n\nhelp@petessences.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nNovember 12, 2024\nRe: CMS Case # 696395\nDear Polly Fox:\nThis letter concerns your firm’s marketing of an unapproved new animal drug for the treatment of seizures in animals, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fpetessences.com\u002F in October to November 2024 and has determined that you offer this product for sale there.\nBased on our review of your website at the internet address https:\u002F\u002Fpetessences.com\u002Fproducts\u002Fseizures, your product is a drug under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, prevention of disease, and\u002For intended to affect the structure or any function of the body of an animal. This product is an unapproved new animal drug and introducing or delivering this product for introduction into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nYou can find the FD&C Act and FDA regulations through links on FDA’s homepage at\nwww.fda.gov.\nThe intended use of your \"Seizures\" product is indicated by its name and is also shown by the claims you make for it. Examples of claims FDA observed on your website and product labeling that show the intended use of your product include, but are not limited to the following:\nFrom your home website titled “Seizures” at the URL https:\u002F\u002Fpetessences.com\u002Fproducts\u002Fseizures:\n• “Our Seizures formula is designed to help reduce the frequency, severity, and duration of seizures in animals.”\n• “We recommend administering it to your pet 2 to 4 times a day to help prevent seizures from occurring.”\n• “…this formula can also be used to manage seizures as they occur.”\n• “…certain physical symptoms like shaking, drooling, and lack of control can be addressed with our formula.”\nOn your home webpage titled “Formulas” at the URL https:\u002F\u002Fpetessences.com\u002Fpages\u002Fformulas?_pos=2&_sid=9eb800182&_ss=r:\n• “At the time of a seizure, use Emergency to help the animal recover. Then use Seizure Prevention to help ease the emotional stress associated with seizures. Use it daily…”\n• “Our Seizures formula is designed to help reduce the frequency, severity, and duration of seizures in animals. We recommend administering it to your pet 2 to 4 times a day to help prevent seizures from occurring. However, this formula can also be used to manage seizures as they occur… certain physical symptoms like shaking, drooling, and lack of control can be addressed with our formula….”\nThis product is a new animal drug under section 201(v) of the FD&C Act, [21 U.S.C. 321(v)], because it is not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. § 360b, 360ccc, and 360ccc-1]. This product is not approved or index listed by FDA, and therefore, the product is unsafe within the meaning of section 512(a) of the FD&C Act, [21 U.S.C. § 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. § 351(a)(5)]. The introduction or delivery for introduction into interstate commerce of an adulterated drug is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\nConclusion\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your product. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all the requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and\u002For injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nPlease direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov. Please include “CMS Case #696395” in the subject line of your email.\nSincerely,\n\u002FS\u002F\nNeal Bataller, ME, DVM\nDirector\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nCc: help@petessences.com","Energetic Essences, LLC dba Pet Essences","energetic-essences-llc-dba-pet-essences-696395-11122024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenergetic-essences-llc-dba-pet-essences-696395-11122024","2026-10-26T08:08:35.538827+00:00","2025-01-07","696395","Animal & VeterinaryDrugs","Polly Fox","2026-08-19T17:05:36.767+00:00","2024-11-12",3,{"510k":74,"classification":75,"enforcement":76,"event":77,"event_backfill":78,"pma":79,"warning_letter":80},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]